Actionable news
0
All posts from Actionable news
Actionable news in GILD: Gilead Sciences, Inc.,

Gilead’s New Hepatitis C Drug Approved by FDA, Priced at $74,760

Gilead’s New Hepatitis C Drug Approved by FDA, Priced at $74,760

  • Epclusa is first treatment for all forms of the disease
  • Drug will mainly be used in patients with genotypes 2 and 3

Gilead Sciences Inc.’s hepatitis C drug was approved by U.S. regulators for all forms of the viral disease, making it the first treatment with such a comprehensive label.

The drug, called Epclusa, can be used by patients with any of the six genotypes of hepatitis C, the U.S. Food and Drug Administration said Tuesday in a statement. The liver disease affects 130 million to 150 million people globally, according to the World Health Organization.

Gilead has set a list price of $74,760 for a 12-week course of treatment, Chief Executive Officer John Milligan said by telephone. That’s lower than the list prices of its best-selling treatments Sovaldi, at $84,000, and Harvoni, $94,500. The Foster City, California-based company has been criticized in the past for the costs of its drugs.

“This is the best price for the system and the company,” said Milligan, noting that Sovaldi and Harvoni are now sold at significant discounts to their list prices.

While Gilead is the market leader in hepatitis C treatments...


More